NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
NeuroPace (NASDAQ: NPCE) announced its participation in the 2024 American Epilepsy Society Annual Meeting (AES 2024) at the Los Angeles Convention Center from December 6-10, 2024. The company's RNS System will be featured in over 70 scientific presentations and posters.
At booth #2119, NeuroPace will showcase their responsive neuromodulation technology, highlighting 82% seizure reduction at three years and improved quality of life without chronic side effects common in other neuromodulation therapies. The company is hosting demonstrations, panels, and networking events, including a Fellows Networking Reception and a Product Theater presentation on 'New Frontiers in Responsive Neuromodulation.'
NeuroPace (NASDAQ: NPCE) ha annunciato la sua partecipazione alla Riunione Annuale della American Epilepsy Society (AES 2024) che si terrà presso il Los Angeles Convention Center dal 6 al 10 dicembre 2024. Il RNS System dell'azienda sarà presentato in oltre 70 presentazioni scientifiche e poster.
Presso lo stand #2119, NeuroPace metterà in mostra la sua tecnologia di neuromodulazione reattiva, evidenziando una riduzione delle crisi dell'82% dopo tre anni e un miglioramento della qualità della vita senza gli effetti collaterali cronici comuni in altre terapie di neuromodulazione. L'azienda ospiterà dimostrazioni, tavole rotonde e eventi di networking, tra cui una Ricezione per i Fellows e una presentazione nel Product Theater su 'Nuove Frontiere nella Neuromodulazione Reattiva.'
NeuroPace (NASDAQ: NPCE) anunció su participación en la Reunión Anual de la American Epilepsy Society (AES 2024) que se llevará a cabo en el Centro de Convenciones de Los Ángeles del 6 al 10 de diciembre de 2024. El RNS System de la empresa será presentado en más de 70 presentaciones científicas y posters.
En el stand #2119, NeuroPace mostrará su tecnología de neuromodulación responsiva, destacando una reducción del 82% en las convulsiones a los tres años y una mejor calidad de vida sin los efectos secundarios crónicos comunes en otras terapias de neuromodulación. La empresa organizará demostraciones, paneles y eventos de networking, incluyendo una Recepción de Networking para Fellows y una presentación en el Product Theater sobre 'Nuevas Fronteras en Neuromodulación Responsiva.'
NeuroPace (NASDAQ: NPCE)는 2024년 12월 6일부터 10일까지 로스앤젤레스 컨벤션 센터에서 개최되는 미국 간질 학회 연례 회의(AES 2024)에 참가한다고 발표했습니다. 회사의 RNS 시스템은 70회 이상의 과학 발표 및 포스터에서 소개될 것입니다.
부스 #2119에서 NeuroPace는 반응형 신경조절 기술을 선보이며, 3년 동안 82%의 발작 감소와 함께 다른 신경조절 요법에서 흔히 나타나는 만성 부작용 없이 향상된 삶의 질을 강조할 것입니다. 회사는 시연, 패널 및 네트워킹 이벤트를 주최하며, Fellows Networking Reception과 '반응형 신경조절의 새로운 경계'에 대한 Product Theater 발표를 포함합니다.
NeuroPace (NASDAQ: NPCE) a annoncé sa participation à la Réunion Annuelle de la American Epilepsy Society (AES 2024) qui se tiendra au Centre de Convention de Los Angeles du 6 au 10 décembre 2024. Le Système RNS de l'entreprise sera présenté dans plus de 70 présentations et affiches scientifiques.
Au stand #2119, NeuroPace fera la démonstration de sa technologie de neuromodulation réactive, mettant en avant une réduction de 82% des crises après trois ans et une amélioration de la qualité de vie sans les effets secondaires chroniques courants dans d'autres thérapies de neuromodulation. L'entreprise organisera des démonstrations, des panels et des événements de mise en réseau, y compris une Réception de mise en réseau pour les Fellows et une présentation au Product Theater sur 'Nouvelles Frontières dans la Neuromodulation Réactive.'
NeuroPace (NASDAQ: NPCE) kündigte seine Teilnahme an der 2024 American Epilepsy Society Annual Meeting (AES 2024) im Los Angeles Convention Center vom 6. bis 10. Dezember 2024 an. Das RNS-System des Unternehmens wird in über 70 wissenschaftlichen Präsentationen und Postern vorgestellt.
Am Stand #2119 wird NeuroPace seine reaktionsfähige Neuromodulationstechnologie präsentieren, wobei eine Reduktion der Anfälle um 82% nach drei Jahren sowie eine Verbesserung der Lebensqualität ohne die häufigen chronischen Nebenwirkungen anderer Neuromodulationstherapien hervorgehoben werden. Das Unternehmen organisiert Demonstrationen, Podiumsdiskussionen und Networking-Veranstaltungen, darunter einen Fellows Networking Reception und eine Präsentation im Product Theater mit dem Titel 'Neue Grenzen in der reaktionsfähigen Neuromodulation.'
- RNS System demonstrates strong clinical efficacy with 82% seizure reduction at three years
- Extensive scientific presence with over 70 presentations and posters at major industry conference
- None.
RNS System to be featured in over 70 scientific presentations and posters
Pre-book a demonstration in the NeuroPace Tech Suite to see the latest innovations of the RNS System which simplify the treatment experience for physicians and patients
NeuroPace’s Booth #2119
MOUNTAIN VIEW, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- December 4, 2024 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will have a substantial presence at the 2024 American Epilepsy Society Annual Meeting (AES 2024). The event is being held at the Los Angeles Convention Center from December 6 - 10, 2024.
“The AES annual meeting is a significant event for NeuroPace and our RNS System. I am excited to announce that the NeuroPace team has put together a strong presence at AES featuring new clinical data on the RNS System, development of AI tools to analyze the intracranial EEG data obtained by the device, product demonstrations and therapy programming workshops during this year’s meeting,” said Martha Morrell, MD, Chief Medical Officer. “Physicians and other attendees will have an opportunity to learn about recent scientific discoveries from data obtained on the RNS System, the latest technology enhancements and to hear how fellow epileptologists, neurosurgeons and other care providers are utilizing this life-changing therapy in their practices.”
The RNS System will be featured at booth #2119, where NeuroPace will highlight the proven outcomes of responsive neuromodulation, including
The NeuroPace team will be available in the NeuroPace booth to provide demonstrations, and in the Tech Suite to gather clinician input on next generation technologies. Customers are invited to schedule an appointment to join one of the RNS System demonstrations. More information is available on the Company’s website: https://www.neuropace.com/december-conference-2024-epilepsy/
Presentation & Event Details:
The Company is sponsoring several panels and networking events during AES. In addition to the following events, NeuroPace is hosting an investigator meeting to review status and progress of key clinical studies including the Nautilus clinical trial and the RNS Post Approval Study.
Fellows Networking Reception:
Title: Doing Well by Doing Good – Practical tips for building a responsive neuromodulation clinic and achieving professional success post-fellowship
Featured Speakers: Fonda Chan, MD, Epileptologist, Neurology Consultants of Dallas, and Deepa Panjeti-Moore, DO, MPH, Epileptologist, Neurology Consultants of Dallas
Date/Time: Friday, December 6, 2024, from 6:30 p.m. - 8:30 p.m. ET
Location: JW Marriott Los Angeles L.A. LIVE, Atrium 2, 3rd Floor
Product Theater:
Title: New Frontiers in Responsive Neuromodulation
Date/Time: Sunday, December 8, 2024, from 2:45 p.m. - 3:45 p.m. ET
Location: Product Theater, Exhibit Hall, Orange County Convention Center
Title: Updates from the RNS System IGE and LGS Trials
Speaker: Martha Morrell, MD, Chief Medical Officer, NeuroPace
Title: Chronic Intracranial EEG Recordings from the Thalamus in IGE and LGS
Speaker: Katie Bullinger, MD, PhD, Associate Professor, Neurology, Emory University School of Medicine
Title: What can AI do for you?
Speaker: Vikram Rao, MD, PhD, Associate Professor, Neurology, UC San Francisco
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
- Razavi, et al., Epilepsia, 2020 (
82% reduction) - Meador, et al., Epilepsy Behavior, 2015 (QOL)
- Loring, et al., Epilepsia, 2015 (QOL)
- Nair, et al., Neurology, 2020 (QOL and side effects)
- Morrell MJ, et al., Neurology, 2011 (side effects)
- Jobst, et al., Epilepsia, 2017 (side effects)
* At therapeutic settings
FAQ
What are the clinical results of NeuroPace's (NPCE) RNS System?
When and where is NeuroPace (NPCE) presenting at AES 2024?
How many scientific presentations will feature NeuroPace's (NPCE) RNS System at AES 2024?
